Drugs / PD-1 knockout Engineered T cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04417764 | Jun 2019 → Dec 2024 | hepatocellular carcinoma | Central South University | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03706326 | Sep 2018 → Sep 2021 | esophageal cancer | The First Affiliated Hospital of Guangdong Pharmaceutical University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PD-1 knockout Engineered T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03706326 ↗ |
| Modality | Cell therapy | “PD-1 knockout Engineered T cells” NCT03706326 ↗ |
| Route | Other | “receive 3 or more cycles of PD-1 knockout engineered T cells infusion by percutaneous fine needle liver puncture” NCT04417764 ↗ |